Seeking Alpha

Peregrine (PPHM) storms 15.6% higher after its bavituximab treatment performed well in a Phase...

Peregrine (PPHM) storms 15.6% higher after its bavituximab treatment performed well in a Phase II trial of 70 patients with advanced Stage IV pancreatic cancer. In combination with the gemcitabine chemotherapy, overall tumor response rates were 28% vs 13% with gemcitabine alone. (PR)
From other sites
Comments (2)
  • TruffelPig
    , contributor
    Comments (4106) | Send Message
     
    Hmm, 17% up now for improvement of MOS from 5.2 to 5.6 month. Is that even statistically significant? Not sure, just saying. Wishing the best to all pancreas cancer patients.
    13 Feb 2013, 09:10 AM Reply Like
  • Oshn33
    , contributor
    Comments (42) | Send Message
     
    Overall survival was the primary endpoint which was only a fraction of a month better than control arm. Ridiculous how this company continues to play with data.
    13 Feb 2013, 09:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs